English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/24593
Compartir / Impacto:
Estadísticas
Add this article to your Mendeley library MendeleyBASE
Ver citas en Google académico
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Título

ROCK and nuclear factor-{kappa}B–dependent activation of cyclooxygenase-2 by Rho GTPases: effects on tumor growth and therapeutic consequences

AutorAznar, Salvador; Valerón, Pilar F.; Lacal, Juan Carlos
Fecha de publicaciónjul-2003
EditorAmerican Society for Cell Biology
CitaciónMolecular Biology of the Cell 14(7): 3041-3054 (2003)
ResumenRho GTPases are overexpressed in a variety of human tumors contributing to both tumor proliferation and metastasis. Recently, several studies demonstrate an essential role of transcriptional regulation in Rho GTPases-induced oncogenesis. Herein, we demonstrate that RhoA, Rac1, and Cdc42 promote the expression of cyclooxygenase-2 (COX-2) at the transcriptional level by a mechanism that is dependent on the transcription factor nuclear factor-{kappa}B (NF-{kappa}B), but not Stat3, a transcription factor required for RhoA-induced tumorigenesis. With respect to RhoA, this effect is dependent on ROCK, but not PKN. Treatment of RhoA-, Rac1-, and Cdc42-transformed epithelial cells with Sulindac and NS-398, two well-characterized nonsteroid antiinflammatory drugs (NSAIDs), results in growth inhibition as determined by cell proliferation assays. Accordingly, tumor growth of RhoA-expressing epithelial cells in syngeneic mice is strongly inhibited by NS-398 treatment. The effect of NSAIDs over RhoA-induced tumor growth is not exclusively dependent on COX-2 because DNA-binding of NF-{kappa}B is also abolished upon NSAIDs treatment, resulting in complete loss of COX-2 expression. Finally, treatment of RhoA-transformed cells with Bay11-7083, a specific NF-{kappa}B inhibitor, leads to inhibition of cell proliferation. We suggest that treatment of human tumors that overexpress Rho GTPases with NSAIDs and drugs that target NF-{kappa}B could constitute a valid antitumoral strategy.
Descripción14 pages, 7 figures.
Versión del editorhttp://www.molbiolcell.org/cgi/content/full/14/7/3041
URIhttp://hdl.handle.net/10261/24593
ISSN1059-1524
Aparece en las colecciones: (IIBM) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
3041.pdf727,56 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo
 


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.